Subscribe To

Price Alert Latest News Economic Calendar News

AZN / AstraZeneca PLC (AZN) Q4 2022 Earnings Call Transcript

AstraZeneca PLC (NASDAQ:AZN ) Q4 2022 Earnings Conference Call February 9, 2023 6:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director & Chief Executive Officer Aradhana Sarin - Executive Director & Chief Financial Officer David Fredrickson - Executive Vice President of Oncology Business Unit Susan Galbraith - Executive Vice President of Oncology Research & Development Ruud Dobber - Executive Vice President of BioPharmaceuticals Business Unit Menelas Pangalos - Executive Vice President of BioPharmaceuticals R&D Marc Dunoyer - Chief Executive Officer of Alexion Iskra Reic - Executive Vice President of Vaccines & Immune Therapies Leon Wang - Executive Vice President of International & China President Conference Call Participants Andrew Baum - Citi Mattias Häggblom - Handelsbanken Timothy Anderson - Wolfe Research Luisa Hector - Berenberg James Gordon - JPMorgan Christopher Uhde - SEB Eric Le Berrigaud - Stifel Mark Purcell - Morgan Stanley Michael Leuchten - UBS Richard Parkes - BNP Paribas Exane Seamus Fernandez - Guggenheim Jo Walton - Credit Suisse Emmanuel Papadakis - Deutsche Bank Operator Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central Europe and good evening to those listening in Asia. Welcome, ladies and gentlemen, to AstraZeneca's Full Year and Q4 2022 Results Conference Call for investors and analysts. Read More

Demo Live Account See Partner Details

Content Topics

Astrazeneca

AZN

2022

Earnings

Call

Transcript

Stock

Posted: Feb 9 2023, 15:03

Author Name: Seeking Alpha

AZN News

By Proactive Investors
November 1, 2023

AstraZeneca inks gene editing deal that could end up costing it $2.5bn

AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS)

By Reuters
November 1, 2023

AstraZeneca signs drug development deal with biotech Cellectis

AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to spee

By Zacks Investment Research
October 31, 2023

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day.

By Zacks Investment Research
October 30, 2023

Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact th

By The Motley Fool
October 28, 2023

3 No-Brainer Stocks to Buy for Under $100 Right Now

AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19.

By Market Watch
October 25, 2023

These healthcare stocks should come to life as boomers live their golden years

Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healt

By Proactive Investors
October 24, 2023

Barclays and AstraZeneca up staff pay as Real Living Wage increases

Employers which pay staff the Real Living Wage (RLW) will have to find an extra 10% after it was increased to £12 in the UK and £13.10 in London on

By Market Watch
October 24, 2023

AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine

AstraZeneca PLC AZN, -1.22% AZN, +1.45% said Tuesday the U.S. Food and Drug Administration has accepted its application for approval of a self-adminis

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.